Mesoblast Stock

Mesoblast P/TBV

Delisted·Jun 19, 2026

The Price to Tangible Book Value (P/TBV) of Mesoblast (MSB.AX) as of Aug 22, 2026 is 74.55. In the previous year, Price to Tangible Book Value (P/TBV) was -20.02 — a change of -472.35% (higher).

P/TBV

74.55

YoY

-472.35%

Last updated:

Price to Tangible Book Value (P/TBV) of Mesoblast is 2026 74.55 . Price to Tangible Book Value (P/TBV) of Mesoblast was 2025 -20.02 . It decreases by -472.35% higher compared to the previous year.
Access this data via the Eulerpool API

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

Price to Tangible Book Value (P/TBV) of Mesoblast is 74.55 in 2026.

Price to Tangible Book Value (P/TBV) of Mesoblast changed from -20.02 to 74.55, representing a -472.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Mesoblast since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Mesoblast with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Mesoblast

All Key Metrics — Mesoblast